Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 65, Issue 12, 2006, Pages 1572-1577

  Van Der Heijde, D ^b   Da Silva, J C ^c   Dougados, M ^d   Geher, P ^e   Van Der Horst Bruinsma, I ^f   Juanola, X ^g   Olivieri, I ^h   Raeman, F ⁱ   Settas, L ^j   Sieper, J ^k   Szechinski, J ^l   Walker, D ^m   Boussuge, M P ⁿ   Wajdula, J S ^a   Paolozzi, L ⁿ   Fatenejad, S ^a  

^a PFIZER INC   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL GARCIA DE ORTA   (Portugal)

^d Cochin Hospital ^*  (France)

^e Hospitaller Brothers of St John of God ^*  (Hungary)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Universitari de Bellvitge ^*  (Spain)

^h SAN CARLO HOSPITAL   (Italy)

ⁱ Jan Palfijn Hospital   (Belgium)

^j AHEPA UNIVERSITY HOSPITAL   (Greece)

^k FREIE UNIVERSITÄT BERLIN   (Germany)

^l WROCLAW MEDICAL UNIVERSITY   (Poland)

^m FREEMAN HOSPITAL   (United Kingdom)

ⁿ Clinical Research and Development   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE;

ADULT; AGED; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYSIPELAS; FEMALE; HUMAN; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 33751302864     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.056747     Document Type: Article

References (22)

1. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
2. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
3. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [comment] [correction appears in N Engl J Med 2001;344:240]. N Engl J Med 2000;343:1586-93.
4. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
5. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [comment]. N Engl J Med 1997;337:141-7.
6. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
7. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis. Lancet 2004;363:675-81.
8. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600.
9. Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, et al. Sustained durability and tolerabilily of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-62.
10. Davis JCJ, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2003;48:3230-6.
11. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl J Med 2002;346:1349-56.
12. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
13. Gorman JD, Sack KE, Davis JC Jr. Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2000;43(9 Suppl):S403.
14. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
15. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12.
16. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
17. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63.
18. Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 1985;24:242-9.
19. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
20. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
21. Calin A, Jones SD, Garrett SL, Kennedy LG. Bath Ankylosing Spondylitis Functional Index. Br J Rheumatol 1995;34:793-4.
22. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.